Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander M.M. Eggermont, Caroline Robert, Christian U. Blank et al.|European Journal of Cancer|2024Cited by 84